Ganesh Venkataraman Kaundinya Sells 1,917 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) COO Ganesh Venkataraman Kaundinya sold 1,917 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $16.00, for a total value of $30,672.00. Following the sale, the chief operating officer now owns 492,845 shares of the company’s stock, valued at approximately $7,885,520. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Ganesh Venkataraman Kaundinya also recently made the following trade(s):

  • On Tuesday, November 21st, Ganesh Venkataraman Kaundinya sold 821 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $13.15, for a total value of $10,796.15.

Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) traded up $0.05 during midday trading on Monday, hitting $16.30. The company had a trading volume of 571,269 shares, compared to its average volume of 921,225. Momenta Pharmaceuticals, Inc. has a fifty-two week low of $11.85 and a fifty-two week high of $19.46. The firm has a market cap of $1,250.00, a PE ratio of -20.38 and a beta of 1.80.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtus Fund Advisers LLC acquired a new position in shares of Momenta Pharmaceuticals during the 4th quarter worth about $1,012,000. BlackRock Inc. lifted its position in shares of Momenta Pharmaceuticals by 0.8% during the 4th quarter. BlackRock Inc. now owns 10,473,316 shares of the biotechnology company’s stock worth $146,105,000 after purchasing an additional 82,691 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Momenta Pharmaceuticals by 16.5% during the 4th quarter. Rhumbline Advisers now owns 175,202 shares of the biotechnology company’s stock worth $2,444,000 after purchasing an additional 24,862 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Momenta Pharmaceuticals by 224.8% during the 4th quarter. Arizona State Retirement System now owns 128,388 shares of the biotechnology company’s stock worth $1,791,000 after purchasing an additional 88,854 shares during the last quarter. Finally, Pinebridge Investments L.P. lifted its position in shares of Momenta Pharmaceuticals by 351.6% during the 4th quarter. Pinebridge Investments L.P. now owns 42,716 shares of the biotechnology company’s stock worth $596,000 after purchasing an additional 33,257 shares during the last quarter. 93.01% of the stock is owned by institutional investors and hedge funds.

MNTA has been the subject of several recent analyst reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Cowen set a $15.00 price target on Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $18.00 price target on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating and ten have assigned a hold rating to the company. The stock has an average rating of “Hold” and a consensus price target of $15.30.

ILLEGAL ACTIVITY WARNING: “Ganesh Venkataraman Kaundinya Sells 1,917 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/12/ganesh-venkataraman-kaundinya-sells-1917-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply